2021-01-04T14:50:47-06:00 2020-03-31 ERNST & YOUNG US LLP 1901 6TH AVE N BIRMINGHAM AL 35203 990 2019-04-01 751835298 Susan G Komen Breast Cancer Fdn Inc % RIA WILLIAMS SUSA 9728551600 13770 Noel Road Suite 801889 Dallas TX 75380 PAULA SUE SCHNEIDER President and CEO 9728551600 2020-12-23 true KATHY PITTS P00292940 2052541608 2019 2022-09-23 18:48:47Z X SUSAN G KOMEN Paula Sue Schneider 13770 Noel Road Suite 801889 Dallas TX 75380 103537546 false 7164 X www.komen.org X 1982 TX SUSAN G KOMENFIGHTS BREAST CANCER ON ALL FRONTS BY DRIVING RESEARCH, PUBLIC POLICY, EDUCATION & SUPPORT SERVICES FOR PEOPLE FACING BREAST CANCER TODAY. 11 11 263 1950 24426 -61611 63291987 59972314 12975072 11229901 15415716 6459076 -1624976 -2874522 90057799 74786769 29481585 1959840 0 0 22862266 24559389 2527973 1917235 17178126 37154373 40447365 92026197 68883829 -1968398 5902940 192149996 151061886 75529111 47670630 116620885 103391256 X SUSAN G. KOMEN IS FIGHTING BREAST CANCER ON ALL FRONTS BY DRIVING RESEARCH, PUBLIC POLICIES, EDUCATION, AND CRITICAL SERVICES TO PEOPLE FACING BREAST CANCER TODAY. false false 32 32476282 495346 0 PROVISION OF BREAST HEALTH/CANCER EDUCATION RESOURCES & PATIENT SUPPORT PROGRAMS WERE MADE POSSIBLE DIRECTLY BY KOMEN AND THROUGH GRANTS TO OTHER NONPROFIT ORGANIZATIONS TO INCREASE THE PUBLIC'S KNOWLEDGE OF BREAST CANCER, ITS RISK FACTORS, THE IMPORTANCE OF EARLY DETECTION & SCREENING, KNOWING WHAT IS NORMAL FOR YOU, LIFESTYLE CHOICES, DIAGNOSIS AND TREATMENT, METASTATIC BREAST CANCER, CLINICAL TRIALS, SOCIAL SUPPORT, COMMUNICATION, COMPLEMENTARY AND INTEGRATIVE THERAPIES, AND COMMUNITY RESOURCES. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 32 5473057 1365119 11260930 GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; NEW STRATEGIES TO TREAT, DETECT, AND PREDICT RISK OF BREAST CANCER, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 32 2399558 99375 538636 PROVISION OF BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS, THIRD-PARTY CONTRACTS AND DIRECTLY BY KOMEN, WITH A SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 40348897 true true false true false false false false false true true true false false false true false true false false true true false true true false false true false true false false false false false false false false true false false false false false false false false true 83 0 true 263 true true true false false false false true true false false false false false false X 11 11 false false true false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X RIA WILLIAMS 9728551600 13770 NOEL ROAD SUITE 801889 Dallas TX 75380 Paula Schneider President and CEO 55.0 0.0 X 631413 0 23166 Christina Alford SVP, Development 55.0 0.0 X 326215 0 19538 Dana Brown CHIEF OPERATING OFFICER 55.0 0.0 X 330938 0 3303 Victoria Wolodzko VP RESEARCH AND COM. HEALTH PR 55.0 0.0 X 260252 0 14182 Catherine Olivieri EN VP, HR and Corporate Secretary 55.0 0.0 X 237337 0 27885 Ria Williams Chief Financial Officer 55.0 0.0 X 229458 0 25918 Linda Fisk SVP, Marketing (END 10/19) 55.0 0.0 X 231553 0 14829 Lori Maris SVP, Affiliate Network 55.0 0.0 X 196203 0 14737 Kimberly Sabelko Sr. Dir., Scientific Strategy 55.0 0.0 X 166787 0 21106 Vanessa Hewitt Sr. Dir., Internal Audit 55.0 0.0 X 168574 0 18979 Sue Aldana VP, Collaborative Revenue 55.0 0.0 X 169301 0 12537 Subhendu Rath END 71 Sr. Dir, IT Enterprise Systems 55.0 0.0 X 169192 0 10402 Eric Montgomery VP, I.T. (END 4/19) 55.0 0.0 X 164984 0 13862 Kimberly Johnson Sr Dir Afri-Am Hlth Equity 55.0 0.0 X 168628 0 2110 Eunice Nakamura BEG 6 Gen Counsel and Corp Secretary 55.0 0.0 X 112770 0 2988 Connie O'Neill BOARD MEMBER (END 6/19) 1.0 0.0 X 0 0 0 Linda Custard BOARD MEMBER (END 6/19) 1.0 0.0 X 0 0 0 Meghan Shannon Brendt BOARD MEMBER (END 6/19) 1.0 0.0 X 0 0 0 Trish Wheaton BOARD MEMBER (END 6/19) 1.0 0.0 X 0 0 0 Angela Zepeda BOARD MEMBER (END 6/19) 1.0 0.0 X 0 0 0 Kim Bohr BOARD MEMBER (END 3/20) 1.0 0.0 X 0 0 0 Andrew Robinson BOARD MEMBER (END 3/20) 1.0 0.0 X 0 0 0 Kaye Ceille BOARD Member 1.0 0.0 X 0 0 0 Doug Knutson MD BOARD Member 1.0 0.0 X 0 0 0 Kristin Nimsger Board Member 1.0 0.0 X 0 0 0 Stephanie Stahl BOARD MEMBER 1.0 0.0 X 0 0 0 Peter D Brundage Chair of the Board 1.0 0.0 X X 0 0 0 John O'Neil Board Member (BEG 6/19) 1.0 0.0 X 0 0 0 Christina Minnis Board Member (BEG 6/19) 1.0 0.0 X 0 0 0 Susannah Gray Board Member (BEG 6/19) 1.0 0.0 X 0 0 0 Jerri Johnson Board Member (BEG 6/19) 1.0 0.0 X 0 0 0 Kwanza Jones Board Member (BEG 6/19) 1.0 0.0 X 0 0 0 Eugene Kim Board Member (BEG 6/19) 1.0 0.0 X 0 0 0 Michael B GreenwaldE BOARD MEMBER & TREASURER 1.0 0.0 X X 0 0 0 3563605 0 225542 54 false true false Event 360 Inc 205 N MICHIGAN AVE CHICAGO IL 60601 EVENT MANAGEMENT 5152908 THE ADVERTISING COUNCIL inc 815 SECOND AVENUE 9TH FLOOR NEW YORK NY 10017 MARKETING 1062811 RKD Group LLC 3400 Waterview Parkway Suite 250 RICHARDSON TX 75080 CONSULTING 732000 Laurel Strategies Inc 4A Oxford Street CHEVY CHASE MD 20815 CONSULTING 480000 Stephen Thomas Ltd 184 FRONT STREET EAST SUITE 501 TORONTO ONTARIO CA M5A 4N3 DIRECT MKTNG SRVCS 458856 18 231422 15804036 43936856 151667 59972314 AFFILIATE PROGRAM FUNDING 900099 11229901 11229901 0 0 11229901 4926211 4926211 0 2627 2627 0 0 0 0 0 0 0 26160315 24627450 1532865 1532865 1532865 377028 15804036 3910284 -3533256 -3533256 0 0 0 0 183725 213043 -29318 -29318 SHARED SERVICES INCOME 900099 598983 598983 0 0 OTHER INCOME 900099 86442 0 24426 62016 685425 74786769 11799566 24426 2990463 X 1959840 1959840 0 0 0 0 2939628 1910758 382152 646718 0 18072553 8545640 5837188 3689725 603167 285307 208225 109635 1711195 757271 623993 329931 1232846 593726 378928 260192 0 118116 53915 21520 42681 341547 341547 241823 241823 1917235 1917235 216323 216323 0 3896089 2623917 80107 1192065 13420103 8005023 130398 5284682 1675406 1089014 217803 368589 0 1076477 488238 456875 131364 1609758 1207377 160498 241883 0 625982 516047 31127 78808 0 0 371810 124950 156036 90824 316930 555 316076 299 CONSULTING & PROF.SVCS. 9708673 8064451 557876 1086346 EVENT PRODUCTION 2703616 2177755 1644 524217 EQUIP. RENTAL & MAINT 1970120 669672 641340 659108 Bank Fees 886930 523629 105291 258010 1267662 509989 491859 265814 68883829 40348897 11356806 17178126 X 39349373 22359038 28566 16961769 0 0 17950693 16576575 26578028 25407636 0 0 0 0 0 0 0 0 217555 110871 1410475 1632025 9670331 8865595 932890 804736 77611324 54648890 67428258 51881153 0 0 0 0 20773 0 192149996 151061886 8480242 7278558 66857399 40205041 191470 187031 0 0 0 0 0 0 0 0 0 0 0 0 75529111 47670630 X 67602118 47196408 49018767 56194848 116620885 103391256 192149996 151061886 X 5902940 -19979434 47998 0 798867 X false true X true false X 105234559 55634984 51441732 63291987 59972314 335575576 0 0 105234559 55634984 51441732 63291987 59972314 335575576 43034806 292540770 2523145 2265964 5667273 5221701 4928838 20606921 0 0 0 0 0 0 336857 51821 124523 34200 86442 633843 356816340 80221196 0.81986 0.83236 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 28198 86368 213625 257094 241823 343462 57285200 113727651 57527023 114071113 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 274215 253525 279269 343462 1150471 250000 250000 250000 250000 1000000 1500000 19341 19478 64115 86368 189302 LOBBYING EXPENSES SCHEDULE C, PART II-A PUBLIC POLICY AND ADVOCACY INITIATIVES HAVE THE POTENTIAL TO IMPACT ALL PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE IMPORTANCE OF THIS WORK TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED ADVOCACY/LOBBYING ACTIVITIES TO ACHIEVE LEGISLATIVE AND REGULATORY SOLUTIONS DESIGNED TO SUPPORT KEY PATIENT PROTECTIONS, EXPAND ACCESS TO HIGH-QUALITY CARE, AND FUND CRITICAL BREAST CANCER RESEARCH. 1333603 9803 5844 1337562 1362090 0 -4016 0 24267 204 1333603 1377855 0 10034 0 25799 0 1362090 1376069 1786 0 1377855 1346721 29808 460 1376069 0.75000 0.24000 0.01000 false false 0 0 0 0 0 0 0 0 610067 361521 248546 0 2561000 2376758 184242 0 6499264 6127316 371948 804736 DEFENSIVE EQUITY FUND 15404153 F PRIVATE EQUITY FUND 36477000 F 51881153 0 0 X Intended use of endowment funds SCHEDULE D, PART V, LINE 4 KOMEN HAS THREE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, AND A GENERAL ENDOWMENT. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, AND THE GENERAL ENDOWMENT'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES. FIN 48 (ASC 740) FINANCIAL STATEMENT DISCLOSURE SCHEDULE D, PART X, LINE 2 THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2020. true Central America and the Caribbean 0 1 Grantmaking Education 4000 East Asia and the Pacific 0 4 Grantmaking Research 497306 Europe (Including Iceland and Greenland) 0 9 Grantmaking Research 574184 Europe (Including Iceland and Greenland) 0 1 Program Services Affiliate Programs 44000 Europe (Including Iceland and Greenland) 0 1 Program Services Membership 43114 Europe (Including Iceland and Greenland) 0 1 Grantmaking Education 40000 Europe (Including Iceland and Greenland) 0 2 Program Services Transportation Service 32267 Europe (Including Iceland and Greenland) 0 2 Program Services Conference Support 23687 Europe (Including Iceland and Greenland) 0 1 Program Services Systm&Softwr Maint&Srv 16189 Europe (Including Iceland and Greenland) 0 1 Program Services Legal Services 3331 Middle East and North Africa 0 1 Program Services Honorarium 1850 North America 0 1 Fundraising Direct Mail Processing 1173024 North America 0 4 Grantmaking Research 412069 North America 0 1 Program Services Video Services 76196 North America 0 1 Program Services Membership 30000 North America 0 3 Program Services Systm&Sftwr Maint&Srv 23545 North America 0 1 Grantmaking Edu, Screening, Trtmnt 15000 North America 0 1 Program Services Affiliate Support 240 Sub-Saharan Africa 0 1 Grantmaking Education 15000 Sub-Saharan Africa 0 2 Program Services Consulting Services 5000 Sub-Saharan Africa 0 1 Program Services Professional Services 2577 0 35 0 5 0 40 3009762 22817 3032579 North America Research 15000 WIRE TRANSFE Europe (Including Iceland and Greenland) RESEARCH 30000 WIRE TRANSFE North America Research 214375 WIRE TRANSFE Europe (including Iceland and Greenland) Education 77974 WIRE TRANSFE East Asia and the Pacific Research 239672 WIRE TRANSFE East Asia and the Pacific Research 292715 WIRE TRANSFE Europe (Including Iceland and Greenland) Research 94188 wire transfe Europe (including Iceland and Greenland) Education 40000 WIRE TRANSFE Europe (including Iceland and Greenland) Research 105390 WIRE TRANSFE North America Research 29998 WIRE TRANSFE Europe (Including Iceland and Greenland) Research 24000 WIRE TRANSFE East Asia and the Pacific Research 36000 WIRE TRANSFE North America Research 34948 WIRE TRANSFE Europe (including Iceland and Greenland) Research 73950 WIRE TRANSFE Sub-Saharan Africa Education 15000 WIRE TRANSFE Europe (Including Iceland and Greenland) 15000 WIRE TRANSFE Europe (Including Iceland and Greenland) Research 149105 WIRE TRANSFE East Asia and the Pacific Research 78710 WIRE TRANSFE North America Research 132748 WIRE TRANSFE 19 false false true false false false PROCEDURES FOR MONITORING USE OF GRANT FUNDS OUTSIDE OF THE UNITED STATES SCHEDULE F, PART I, LINE 2 AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT SCIENTIFIC PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV and SCHEDULE O, Part IX, Line 1 narrative FOR ADDITIONAL DETAILS. X X X X X X true Event 360 Fundraising Consultant false 16824447 1288227 15536220 RKD GROUP LLC Fundraising Consultant false 14742827 370550 14372277 BOB CARTER COMPANIES FUNDRAISING Consultant false 0 68251 0 BLUE STATE DIGITAL INC Marketing Consultant false 0 61468 0 Revunami Inc Marketing Consultant false 0 59810 0 REDPEG MARKETING Marketing Consultant false 995 50463 0 THE DALTON AGENCY Marketing Consultant false 0 9450 0 TURNKEY PROMOTIONS INC Marketing Consultant false 0 9015 0 31568269 1917234 29908497 AL AK AZ AR CA CO CT DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY 3 Day 7 15197300 14917986 279314 0 155290 1238318 1352226 0 1082299 DC Walk 1 858115 760401 97714 0 6283 51813 14741 0 4163 1 125649 125649 0 3200 0 1500 0 451 16181064 15804036 377028 0 164773 1290131 1368467 0 1086913 3910284 -3533256 SCHEDULE G PART I THE MAJORITY OF FUNDRAISING CONSULTING COSTS WITHOUT CORRESPONDING GROSS RECEIPTS ARE ASSOCIATED WITH KOMEN'S AFFILIATE NETWORK FUNDRAISING EFFORTS. THE GROSS RECEIPTS ARE RETAINED BY THE AFFILIATES. NET INCOME SUMMARY SCHEDULE G PART II GROSS RECEIPTS ARE REDUCED BY THE AMOUNT OF CONTRIBUTIONS, PER IRS INSTRUCTIONS. THE CONTRIBUTIONS FOR FISCAL YEAR 2020 WERE $15,804,036. true African Women's Cancer Awareness Assoc 8955 Edmonston Road Greenbelt MD 20770 731704355 501c3 58810 Treatment Albany Medical College 47 NEW SCOTLAND AVE ALBANY NY 12208 141338310 501c3 90000 Research American Association for Cancer Research 615 Chestnut PHILADELPHIA PA 19106 236251649 501c3 110000 Research American Assoc on Health & Disability 110 N WASHINGTON ROCKVILLE MD 20850 521884887 501c3 20000 Education, Screening Arlington Free Clinic 2921 11TH STREET SOUTH ARLINGTON VA 22204 541671883 501c3 59999 Treatment Baylor College Medicine ONE BAYLOR PLAZA HOUSTON TX 770303411 741613878 501c3 868347 RESEARCH Beth Israel Deaconess Medical Center RES FIN OFFICE BOSTON MA 02215 042103881 501c3 149510 Research Boat People SOS 60066 LEESBURG PIKE FALLS CHURCH VA 22041 541563619 501c3 14018 TREATMENT Boston University 580 Harrison Ave 3-W BOSTON MA 02118 042103547 501c3 127000 RESEARCH Breast Care for Washington 4 ATLANTIC ST SW WASHINGTON DC 20032 455574713 501c3 100000 Screening, treatment Brigham & Women's Hospital 181 LONGWOOD AVE 5TH FL BOSTON MA 02115 042312909 501c3 100000 Research Burnham Institute for Medical Research CANCER CTR LA JOLLA CA 92037 510197108 501c3 124986 RESEARCH Cancer Care 275 SEVENTH AVENUE NEW YORK NY 10001 131825919 501c3 2874966 EDUCATION, TREATMENT CASA of Maryland Inc 8151 15TH AVE HYATTSVILLE MD 20783 521372972 501c3 10000 TREATMENT Children's Hospital Boston PO BOX 414413 BOSTON MA 022414413 042774441 501c3 24000 RESEARCH Columbia University Medical Center 722 W 168TH ST 4TH FL NEW YORK NY 10032 135598093 501c3 373899 Research Dana Farber Cancer Institute 44 BINNEY ST BOSTON MA 02115 042263040 501c3 2305848 Research Duke University Medical Center PO Box 602651 Charlotte NC 282602651 560532129 501c3 225952 Research Ethiopian Community Development Council 901 S HIGHLAND ST ARLINGTON VA 22204 521308986 501c3 20000 TREATMENT Facing Our Risk of Cancer Empowered 16057 TAMPA PALMS BLVD TAMPA FL 33647 650927702 501c3 24000 EDUCATION Fred Hutchinson Cancer Research Center PO BOX 19024 MS J6-330 SEATTLE WA 90109 563744111 501c3 387990 Education, Research H Lee Moffitt Cancer Center 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238636 501c3 157200 Research Harvard Medical School HOLYOKE CENTER RM 600 CAMBRIDGE MA 02138 042103580 501c3 186000 RESEARCH Indiana U (Indianapolis) PO BOX 66057 INDIANAPOLIS IN 462666057 356001673 501c3 1429984 RESEARCH Johns Hopkins University 1101 East 33rd Street BALTIMORE MD 21218 520595110 501c3 1485999 Education, Research Kingman Regional Medical Center 3269 STOCKTON HILL RD KINGMAN AZ 86409 742388735 501c3 21927 Education, Treatment Korean Community Svc Ctr of Greater WA 7700 LITTLE RIVER TRNPK ANNANDALE VA 22003 386005984 501c3 10212 SCREENING, TREATMENT Leland Stanford Jr University PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501c3 209074 RESEARCH Living Beyond Breast Cancer 354 WEST LANCASTER AVE HAVERFORD PA 19041 530196932 501c3 6000 Education Maricopa Health Foundation 2910 E CAMELBACK ROAD PHOENIX AZ 85016 860777567 501c3 7500 TREATMENT Mary's Ctr for Maternal&Child Care Inc 2333 ONTARIO ROAD NW WASHINGTON DC 20009 521594116 501c3 100000 Education, TREATMENT Massachusetts General Hospital PO BOX 414876 BOSTON MA 022414876 042697983 501c3 24000 Research Massachusetts Institute of Technology 160 MEMORIAL DRIVE CAMBRIDGE MA 02139 042103594 501c3 242269 RESEARCH Mayo Clinic Jacksonville GRIFFIN Bldg RM 170 JACKSONVILLE FL 32224 593337028 501c3 280388 Research Mayo Clinic Rochester PO BOX 4008 ROCHESTER MN 559034008 416011702 501c3 120000 Research Medical College of Wisconsin Heidi Brittnacher Div of Surgical Milwaukee WI 53226 390806261 501c3 90000 Research Memorial Sloan-Kettering Cancer Ctr 633 3RD AVENUE 28TH FL NEW YORK NY 10017 131924236 501c3 350000 RESEARCH METAvivor Research and Support 1783 FOREST DR ANNAPOLIS MD 21403 371578088 501c3 25000 EDUCATION Mount Sinai School of Medicine ONE GUSTAVE L LEVY PL NY NY 10029 136171197 501c3 300000 RESEARCH Mountain Park Health Cntr 3003 N 3RD ST STE 1600 PHOENIX AZ 85012 860498020 501c3 39167 EDUCATION, SCREENING, TREATMENT Northwestern University - Chicago 633 CLARK EVANSTON IL 60208 362167817 501c3 417097 Research Nueva Vida Inc 2000 P STREET NW WASHINGTON DC 20036 541943145 501c3 99090 Education, Treatment Obesity Society 8757 GEORGIA AVENUE SILVER SPRING MD 20910 541438429 501c3 16000 Research Oregon Health & Science University 0690 SW Bancroft PORTLAND OR 97239 752668014 501c3 529024 Research Partners for Cancer Care and Prevention 10 E LEE ST UNIT 1901 BALTIMORE MD 21202 451605551 501c3 7500 SCREENING Princeton University 701 CARNEGIE CENTER PRINCETON NJ 08540 210634501 501c3 176000 Research Providence Portland Medical Center PO Box 13993 PORTLAND OR 97213 930386906 501c3 150000 Research Purdue University 23510 NETWORK PL CHICAGO IL 606731235 356002041 501c3 120000 Research Rockefeller University 1230 YORK AVE BOX 164 NEW YORK NY 10065 131624158 501c3 60000 Research Stanford University PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501c3 315912 Research SUNY at Stony Brook W5510 Melville Lib STONY BROOK NY 11794 146013200 501c3 404745 Research The Ohio State University College 700 Childrens Dr COLUMBUS OH 43205 316025986 501c3 245000 Research The Salk Institute 10010 N Torrey PNS RD LA JOLLA CA 92037 376000511 501c3 157158 Research The University of Chicago 5801 S Ellis Ave CHICAGO IL 60637 362177139 501c3 228704 Research The University of Toledo 2801 W Bancroft ST TOLEDO OH 436063390 346401483 501c3 149645 Research The Wistar Institute 3601 SPRUCE ST PHILADELPHIA PA 191044265 236434390 501c3 240000 Research Trustees of Columbia Univ SPONSORED PROJECTS FINANCE NEW YORK NY 10027 135598093 501c3 30000 Research Univ of North Carolina at Chapel Hill 104 AIRORT DR CHAPEL HILL NC 275991350 566001393 501c3 926194 Research Univ of Texas MD Anderson Cancer Center PO Box 4390 HOUSTON TX 772104390 746001118 501c3 350686 Research University of Alabama at Birmingham 1530 3RD AVE S BIRMINGHAM AL 352940111 636005396 501c3 179995 Research University of California-Davis PO Box 989062 W SACRAMENTO CA 957989062 956006143 501c3 23994 Research University of California-Los Angeles 10920 Wilshire BLVD LOS ANGELES CA 90024 956006143 501c3 84000 Research University of California-San Francisco 1600 Divisadero St SAN FRANCISCO CA 94118 946036493 501c3 334000 Research University of Kansas Center for Research 2385 IRVING HILL ROAD LAWRENCE KS 66045 480680117 501c3 150000 Research University of Kansas Medical Center 3901 Rainbow BLVD KANSAS CITY KS 66160 481108830 501c3 60000 Research University of Kentucky Research Fndn 500 S Limestone LEXINGTON KY 405260001 616033693 501c3 59899 Research University of Miami School of Medicine 1475 NW 12th Ave Miami FL 33136 590624458 501c3 23403 RESEARCH University of Michigan Alexandra Thebaud Ann Arbor MI 481091274 386006309 501c3 340000 Research University of Notre Dame du Lac 836a Grace Hall Notre Dame IN 46556 350868188 501c3 150000 RESEARCH University of Pennsylvania 3451 Walnut St Philadelphia PA 191046205 231352685 501c3 1028640 Research University of Pittsburgh 123 University Pl Pittsburgh PA 152132303 250966691 501c3 94141 RESEARCH University of South Carolina 1600 Hampton St Columbia SC 29208 576001153 501c3 81000 RESEARCH University of Southern California 3500 S Figueroa St Los Angeles CA 90089 951642394 501c3 148688 RESEARCH University of Texas at Health Science Ctr Elizabeth Frantz Houston TX 77030 741587488 501c3 81000 RESEARCH University of Utah 201 S Pres Cr Salt Lake City UT 84112 876000525 501c3 353314 RESEARCH University of Virginia at School of Med POBox 400195 Charlottesville VA 229044195 237173411 501c3 90000 RESEARCH University of Washington 3917 Univ Way NE Seattle WA 98105 916001537 501c3 595000 RESEARCH University of Wisconsin - Madison 21 North Park St Madison WI 537151218 396006492 501c3 66415 RESEARCH UT HSC - San Antonio 7703 Floyd Curl Dr San Antonio TX 77229 741586031 501c3 348750 RESEARCH UT Southwestern Medical Center UT Sw Grants Mgmt Dallas TX 752841753 746000203 501c3 369994 RESEARCH Utah Cancer Control Program PO Box 144620 Salt Lake City UT 841144620 876000545 501c3 114959 Education, Screening UTMD Anderson Cancer Ctr 1515 Holcombe Blvd Houston TX 770304009 746001118 501c3 448205 RESEARCH Vanderbilt University Medical Center 1161 21st Ave S Atlanta GA 31192 620476822 501c3 773586 RESEARCH Virginia Commonwealth University 800 E Leigh St Richmond VA 23284 546001758 501c3 300000 RESEARCH Wake Forest University Health Sciences MEDICAL CNTR BLVD WinstonSalem NC 27157 223849199 501c3 150000 RESEARCH Washington University at St Louis 700 Rosedale Ave Saint Louis MO 63112 430653611 501c3 420146 RESEARCH Wayne State University 5057 WOODWARD AVE Detroit MI 48202 366028429 501c3 60000 RESEARCH Weill Medical College of Cornell Univ 1300 York Avenue New York NY 10061 131623978 501c3 367122 RESEARCH Wesley Community Center 1300 S 10th Street Phoenix AZ 85034 860133770 501c3 22332 Education, Treatment Yale University 2 Whitney Avenue New Haven CT 06521 060646973 501c3 157211 RESEARCH Coriell Institute for Medical Research 403 Haddon Avenue Camden NJ 081031505 210672684 501c3 33919 Research ECOG Research and Education Foundation 1818 Market Street Philadelphia PA 19109 391723095 501c3 22969 Research Emory University 1599 Clifton Rd NE Atlanta GA 303224250 580566256 501c3 148318 Research Georgetown U PO BOX 571164 Washington DC 200571164 530196603 501c3 25883 Research Georgetown University 37th O ST NW Washington DC 200570004 522339873 501c3 60000 Research Intermountain Healthcare Foundation Inc 36 S State ST Salt Lake City UT 84111 942854057 501c3 18750 Education Neighborhood Health 6677 RICHMOND HWY Alexandria VA 22305 541849891 501c3 48313 Education, Treatment North Country Healthcare Inc 2920 N 4th Street Flagstaff AZ 860041816 860663432 501c3 24167 Education, Treatment Ohio State Univ Research Foundation 1960 KENNY RD 4TH FL Columbus OH 43210 316025986 501c3 40000 Research Rush University Medical Center 1700 W Van Buren St Chicago IL 60612 362174823 501c3 100165 Research The Massachusetts General Hospital PO Box 414876 Boston MA 022414876 042697983 501c3 129749 Research The University of Texas at Austin Communications Career Services Austin TX 78712 746000203 501c3 150000 Research Tufts University 800 Washington Street Boston MA 02111 042985923 501c3 60000 Research University of Arizona Bursar/Sponsored Projects Tucson AZ 857334390 742652689 501c3 29990 Research University of Chicago 5801 S Ellis Ave Chicago IL 60637 382177139 501c3 150000 Research University of Cincinnati 51 Goodman Dr Cincinnati OH 452210222 316000989 501c3 30000 Research University of Colorado Denver 13001 E 17th Place Aurora CO 800452571 846000555 501c3 36000 Research University of Pittsburgh 3100 CTHDRL of Learn Pittsburgh PA 15260 250965591 501c3 579109 Research Valleywise Health Foundation 2901 E Camelback Rd Phoenix AZ 85016 860777567 501c3 16667 Education Recinto de Ciencias Medicas PO BOX 365067 SAN JUAN PR 009365067 660433762 501c3 18797 Treatment 110 PROCEDURES FOR MONITORING THE USE OF GRANTS SCHEDULE I, PART I, LINE 2 SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR EDUCATION, SCREENING, AND TREATMENT GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, Part IX, Line 1 narrative FOR ADDITIONAL DETAILS. X true true X X X X X X true false false false false false false false false Subhendu Rath END 719 Sr. Dir, IT Enterprise Systems 130017 0 0 0 39175 0 7414 0 2988 0 179594 0 0 0 Vanessa Hewitt Sr. Dir., Internal Audit 166701 0 0 0 1873 0 10468 0 8511 0 187553 0 0 0 Paula Schneider President and CEO 576289 0 50000 0 5124 0 14949 0 8217 0 654579 0 0 0 Catherine Olivieri END 619 VP, HR and Corporate Secretary 233509 0 0 0 3828 0 14723 0 13162 0 265222 0 0 0 Dana Brown CHIEF OPERATING OFFICER 328136 0 0 0 2802 0 0 0 3303 0 334241 0 0 0 Ria Williams Chief Financial Officer 227125 0 0 0 2333 0 11616 0 14302 0 255376 0 0 0 Christina Alford SVP, Development 294114 0 30000 0 2101 0 16724 0 2814 0 345753 0 0 0 Victoria Wolodzko VP RESEARCH AND COM. HEALTH PR 233936 0 24000 0 2316 0 11546 0 2636 0 274434 0 0 0 Lori Maris SVP, Affiliate Network 193368 0 0 0 2835 0 7785 0 6952 0 210940 0 0 0 Eric Montgomery VP, I.T. (END 4/19) 118436 0 0 0 46548 0 5944 0 7918 0 178846 0 0 0 Linda Fisk SVP, Marketing (END 10/19) 228982 0 0 0 2571 0 8352 0 6477 0 246382 0 0 0 Sue Aldana VP, Collaborative Revenue 166169 0 0 0 3132 0 9296 0 3241 0 181838 0 0 0 Kimberly Sabelko Sr. Dir., Scientific Strategy 164099 0 0 0 2688 0 10439 0 10667 0 187893 0 0 0 Kimberly Johnson Sr Dir Afri-Am Hlth Equity 165528 0 0 0 3100 0 0 0 2110 0 170738 0 0 0 FORM 990, SCHEDULE J, PART I, LINE 1A SUPPLEMENTAL COMPENSATION INFORMATION SUSAN G. KOMEN'S TRAVEL POLICY DOES NOT REIMBURSE FOR FIRST CLASS OR BUSINESS CLASS TRAVEL. HOWEVER, PERSONAL FREQUENT FLIER MILEAGE AND COUPONS MAY BE USED FOR NO COST UPGRADES. IN THE EVENT OF INTERNATIONAL TRAVEL WITH FLIGHT TIMES OF SIX HOURS OR MORE, AND PRE-APPROVAL, BUSINESS OR FIRST CLASS TRAVEL MAY BE PERMITTED IF THERE IS A MEDICAL ACCOMMODATION OR BUSINESS PURPOSE. WHENEVER POSSIBLE, DISCOUNTED FIRST CLASS AND FREE UPGRADES ARE USED TO MINIMIZE COSTS. FORM 990, SCHEDULE J, PART I, LINE 4A SEVERANCE PAYMENT Subhendu Rath RECEIVED A SEVERANCE PAYMENT OF $37,959. Eric Montgomery RECEIVED A SEVERANCE PAYMENT OF $45,409. X 128311 FMV X 5 3856 FMV X Airline Miles 1 18000 FMV X Storage Facility 1 1500 FMV false true false SCHEDULE M, PART I, COLUMN (B) THE AMOUNTS IN THIS COLUMN REPRESENTS THE NUMBER OF ITEMS CONTRIBUTED OTHER THAN FOOD, WHICH IS NUMBER OF CONTRIBUTIONS. FORM 990, PART I, QUESTION 6 - VOLUNTEERS VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE SUSAN G. KOMEN 3 DAY SERIES. FORM 990, PART III - PROGRAM SERVICE ACCOMPLISHMENTS SUSAN G. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE THE U.S. GOVERNMENT WHILE PROVIDING REAL TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS FUNDED MORE THAN $1 BILLION IN BREAST CANCER RESEARCH AND PROVIDED OVER $2.3 BILLION IN FUNDING FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, AND DEVELOPING NEW APPROACHES TO ADDRESS DISPARITIES IN BREAST CANCER OUTCOMES, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS, TECHNOLOGIES AND INTERVENTIONS. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 59 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY20, KOMEN AWARDED 4 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, IN THE UNITED STATES. THESE GRANTS FOCUSED ON RESEARCH DESIGNED TO UNDERSTAND AND ADDRESS THE BIOLOGIC, BEHAVIORAL, SOCIAL AND SYSTEMIC CAUSES OF BREAST CANCER DISPARITIES. THE 4 DISPARITIES RESEARCH GRANTS AWARDED IN FY20 ARE: 1. Bryan Schneider, M.D., of Indiana University in Indianapolis, IN will study how genetic ancestry affects how African American women respond to breast cancer therapy, especially treatment induced side effects. He is especially interested in how mutations in a gene called SBF2 affect the development of taxane-induce peripheral neuropathy), a serious side effect linked to worse outcomes in African American patients. Dr. Schneider will also build a decision-making tool that will help African American patients work with their physicians to make the best treatment decisions. 2. Anne Rositch, Ph.D., of Johns Hopkins University in Baltimore, MD will address the disparity in breast cancer mortality in low resource settings by implementing and evaluating patient advocacy, navigation, and referral programs in Tanzania. This work will help patients overcome barriers to care that result in delays in treatment, late-stage diagnosis, or failure to complete treatment. By developing community-based programs to help patients stay in the continuum of care, this work can improve breast cancer outcomes in low-income areas across the globe. 3. Harikrishna Nakshatri, Ph.D., of Indiana University in Indianapolis, IN will study how genetic ancestry affects breast cancer biomarkers in women of African American and European ancestry. He will develop a tissue microarray platform to compare tiny samples of breast tumor, tissue around the tumors (tumor microenvironment), and normal breast tissue (using samples from the Komen Tissue Bank) from women of African, European and other ancestries. He will study how breast tissue biology differs between these populations and how genetic ancestry can impact breast cancer outcomes. These studies will shed light on the genetic factors affecting disparities in outcomes for AA breast cancer patients, and inform the development of better genetic biomarkers for early breast cancer detection for people of different genetic ancestry. 4. Mary-Claire King, Ph.D., of The University of Washington in Seattle, WA will use new genomic approaches to find the genetic basis for the higher rate of TNBC in African American women. Current sequencing technologies have been unable to identify mutations that might explain these higher rates of inherited TNBC. Dr. King will study the role of complex genetic mutations (such as deletion or insertion of large amounts of genetic material), that are not detectable by standard sequencing methods, in over 80 cases of inherited TNBC in African American women. These studies will address the gap in knowledge about genetics of TNBC in African American women, which will help inform treatment decisions and improve outcomes in AA women diagnosed with TNBC. EDUCATION AND PATIENT SUPPORT KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE "ABOUT BREAST CANCER" SECTION OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBERCANCER INSTITUTE STAFF, RECEIVED MORE THAN 5 MILLION PAGE VIEWS DURING FY20. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACTSHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) TOOLKITS FOR BREAST CANCER OUTREACH AND EDUCATION FOR HISPANIC/LATINO IN ENGLISH AND SPANISH AND FOR BLACK AND AFRICAN-AMERICAN COMMUNITIES. THE SUSAN G. KOMEN "1-877 GO KOMEN" (1-877-465-6636) BREAST CARE HELPLINE OFFERS BREAST CANCER EDUCATION, PSYCHOSOCIAL SUPPORT, AND INFORMATION ABOUT COMMUNITY RESOURCES FOR PATIENTS, FAMILIES, AND THE GENERAL PUBLIC. THE CLINICAL TRIAL INFORMATION HELPLINE PROVIDES INFORMATION, RESOURCES, COACHING AND SUPPORT RELATED TO BREAST CANCER CLINICAL TRIALS. THE HELPLINE OPERATES FROM 9 A.M. - 10 P.M. E.T. THE SERVICE IS OFFERED IN ENGLISH, SPANISH, AND TAGALOG. DURING FY20, THE KOMEN HELPLINE RESPONDED TO MORE THAN 15,000 CALLS AND EMAILS. IN ADDITION, IN FY20 KOMEN DEVELOPED AND DELIVERED A CONFERENCE FOR WOMEN LIVING WITH METASTATIC BREAST CANCER IN THE WASHINGTON, D.C. REGION. THE CONFERENCE BRINGS PEOPLE WITH METASTATIC BREAST CANCER, CAREGIVERS, HEALTHCARE PROFESSIONALS, HEALTHCARE ORGANIZATIONS, SUPPORT ORGANIZATIONS AND OTHERS TOGETHER, WHO PARTICIPATE IN THE CARE OF PATIENTS WITH METASTATIC BREAST CANCER, TO DISCUSS SCIENTIFIC BREAKTHROUGHS, ONGOING CLINICAL TRIALS, QUALITY OF LIFE, AND INTEGRATIVE MEDICINE. THE CONFERENCE IS DESIGNED TO FILL THE NEEDS OF THE METASTATIC BREAST CANCER COMMUNITY AND SEEKS TO STRENGTHEN METASTATIC BREAST CANCER VOICES IN THE NATIONAL CAPITAL REGION BY CREATING OPPORTUNITIES FOR LEARNING, ENGAGEMENT AND ACTION. BREAST CANCER IS THE MOST COMMON CANCER IN WOMEN, WORLDWIDE, AND THE NUMBER OF CASES IS INCREASING IN NEARLY EVERY COUNTRY. THE NUMBER OF NEW BREAST CANCER CASES HAS MORE THAN DOUBLED AROUND THE WORLD IN THE LAST THREE DECADES, WITH HIGHEST INCREASES OBSERVED IN LOW- AND MIDDLE-INCOME COUNTRIES. THESE TRENDS ARE CONCERNING, WHICH IS WHY KOMEN WORKS TIRELESSLY TO PROVIDE SUPPORT TO BREAST HEALTH PROGRAMS WORLDWIDE. IT TAKES COLLABORATION AND STRONG PARTNERSHIPS TO MAKE A GLOBAL IMPACT. KOMEN STRIVES TO SERVE AS A "BRIDGE" - COLLABORATING WITH INTERNATIONAL NONPROFITS, CORPORATIONS, AND MINISTRIES OF HEALTH TO BRING TOGETHER PEOPLE AND ORGANIZATIONS TO DEVELOP PROGRAMS THAT ARE TAILORED TO THE SPECIFIC NEEDS OF THE COMMUNITY AND SENSITIVE TO CULTURAL DIFFERENCES. IN FY20, KOMEN'S GLOBAL PROGRAM CONTINUED ITS COLLABORATIVE WORK TO SUPPORT EDUCATION PROGRAMMING FOR PATIENTS AND FOR HEALTH PROFESSIONALS AND TO REDUCE BARRIERS TO BREAST CANCER CARE IN LATIN AMERICA AND AFRICA. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE OF MORE THAN 3.8 MILLION BREAST CANCER SURVIVORS, THOSE LIVING WITH THE DISEASE AND THE PEOPLE WHO LOVE THEM. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES, SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS, AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THROUGH OUR CENTER FOR PUBLIC POLICY, KOMEN ENSURES THAT OUR POLICYMAKERS ARE EDUCATED ABOUT THE NEEDS OF BREAST CANCER PATIENTS AND PRIORITIZE THE ISSUES IMPACTING THEM. ONLY THROUGH INFORMED GOVERNMENT ACTION CAN WE MAKE THE BROAD, SYSTEMIC AND LASTING CHANGE REQUIRED. EVERY TWO YEARS, THROUGH A TRANSPARENT, BROAD-BASED AND INTENSIVE VETTING AND SELECTION PROCESS, KOMEN WORKS TO IDENTIFY THE POLICY ISSUES WITH THE GREATEST POTENTIAL IMPACT. THIS PROCESS INCLUDES COLLECTING FEEDBACK FROM KOMEN AFFILIATES FROM ACROSS THE COUNTRY; ADVISORY GROUPS INCLUDING ADVOCATES IN SCIENCE (AIS) AND KOMEN SCHOLARS; REPRESENTATIVES FROM THE METASTATIC BREAST CANCER COMMUNITY AND KOMEN'S AFRICAN AMERICAN HEALTH EQUITY INITIATIVE; AND OTHER STAKEHOLDERS WITH A VESTED INTEREST IN BREAST CANCER-RELATED ISSUES. THE SELECTED ISSUES ARE THE BASIS FOR KOMEN'S STATE AND FEDERAL ADVOCACY EFFORTS. KOMEN'S 2019-2020 PUBLIC POLICY AND ADVOCACY PRIORITIES INCLUDED: EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING; AND EVALUATING STATE AND FEDERAL POLICIES TO INCREASE PUBLIC ACCESS TO INFORMATION ABOUT AND PARTICIPATION IN CLINICAL TRIALS FOR ALL PATIENT POPULATIONS. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR PUBLIC POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO, COMPASSIONATE USE, CUSTOM BREAST PROTHESES, GENETIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK. SCREENING AND PATIENT NAVIGATION GETTING REGULAR SCREENING TESTS, ALONG WITH EFFECTIVE AND QUALITY TREATMENT IF DIAGNOSED, LOWERS THE RISK OF DYING FROM BREAST CANCER. SCREENING TESTS CAN FIND BREAST CANCER EARLY, WHEN CHANCES FOR SURVIVAL ARE HIGHEST. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM. EVIDENCE SHOWS NAVIGATION IMPROVES ADHERENCE TO SCREENING RECOMMENDATIONS, AND THUS IMPROVES OVERALL OUTCOMES. KOMEN SUPPORTS FREE AND LOW-COST SCREENING PROGRAMS IN UNDERSERVED COMMUNITIES THAT HELP NAVIGATE PEOPLE TO QUALITY CARE, AND/OR PROVIDE COVERAGE FOR SCREENING SERVICES TO PEOPLE WITHOUT HEALTH INSURANCE, OR THOSE WITH HIGH CO-PAYS AND DEDUCTIBLES THAT MAKE SCREENING TOO COSTLY. KOMEN AWARDED ONE SCREENING COMMUNITY GRANT TO BREAST CARE FOR WASHINGTON, TO DEVELOP A MOBILE MAMMOGRAPHY PROJECT TO INCREASE ACCESS TO QUALITY SCREENING AND NAVIGATE WOMEN INTO DIAGNOSIS AND TREATMENT. TREATMENT AND PATIENT NAVIGATION BARRIERS TO QUALITY CARE ARE OFTEN ASSOCIATED WITH POOR BREAST CANCER OUTCOMES AND RESULTANT CANCER DISPARITIES AMONG SPECIFIC POPULATION GROUPS. ACCORDING TO QUALITATIVE DATA COLLECTED FROM ACROSS KOMEN'S AFFILIATE NETWORK, THE MOST COMMON BARRIERS TO QUALITY CARE IN THE UNITED STATES INCLUDE: (1) AVAILABILITY OF LOCAL SERVICES; (2) BREAST CANCER EDUCATION; (3) CULTURAL/LANGUAGE; (4) FEAR; (5) FINANCIAL; (6) INSURANCE; (7) TRANSPORTATION. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL - A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM TO ENSURE TIMELY DIAGNOSIS AND TREATMENT. EVIDENCE SHOWS PATIENT NAVIGATION IMPROVES ADHERENCE TO TREATMENT RECOMMENDATIONS, RESULTING IN IMPROVED OUTCOMES. KOMEN FUNDED THREE NONPROFIT ORGANIZATIONS IN SUPPORT OF PROGRAMS TO REDUCE STRUCTURAL, PERSONAL, SOCIOCULTURAL, AND FINANCIAL BARRIERS TO CARE, AND PROVIDE PATIENT NAVIGATION SERVICES FOR UNDERSERVED COMMUNITIES IN THE WASHINGTON, D.C. METRO AREA, SPECIFICALLY WARDS 2, 5, 7, AND 8, AND ALEXANDRIA CITY, VA. KOMEN'S TREATMENT ASSISTANCE PROGRAM, ADMINISTERED BY CANCERCARE, AIMS TO HELP WOMEN AND MEN IN BREAST CANCER TREATMENT WHO ARE FACING FINANCIAL CHALLENGES STAY IN TREATMENT BY PROVIDING LIMITED FINANCIAL ASSISTANCE, EDUCATION, AND SUPPORT SERVICES. FINANCIAL ASSISTANCE IS GRANTED TO UNDERSERVED, UNDERINSURED OR UNINSURED WOMEN AND MEN ACROSS THE COUNTRY UNDERGOING BREAST CANCER TREATMENT WHO MEET PRE-DETERMINED ELIGIBILITY CRITERIA. THIS PROGRAM PROVIDES FINANCIAL ASSISTANCE FOR TREATMENT-RELATED COSTS, INCLUDING TRANSPORTATION TO AND FROM TREATMENT, CHILD/ELDER CARE, HOME CARE, ORAL PAIN/ANTI-NAUSEA MEDICATIONS, ORAL CHEMOTHERAPY/HORMONE THERAPY, LYMPHEDEMA CARE/SUPPLIES, PALLIATIVE CARE, AND DURABLE MEDICAL EQUIPMENT. WE SERVED MORE THAN 4400 PEOPLE THROUGH THIS PROGRAM IN FY20. EXECUTIVE COMMITTEE FORM 990, PART VI, LINE 1A THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES. ON MARCH 24, 2020, THE BOARD OF DIRECTORS UNANIMOUSLY ADOPTED THE SIXTH AMENDED AND RESTATED BYLAWS, WHICH, AMONG OTHER THINGS, EXPANDED THE MAXIMUM NUMBER OF DIRECTORS FROM 15 TO 19 AND REQUIRED THE ANNUAL MEETING OF THE BOARD OF DIRECTORS TO TAKE PLACE WITHIN 90 DAYS BEFORE THE EXPIRATION OF THE FISCAL YEAR. CHANGES TO ORGANIZATION BYLAWS FORM 990, PART VI, LINE 4 ON MARCH 24, 2020, THE BOARD OF DIRECTORS UNANIMOUSLY ADOPTED THE SIXTH AMENDED AND RESTATED BYLAWS, WHICH, AMONG OTHER THINGS, EXPANDED THE MAXIMUM NUMBER OF DIRECTORS FROM 15 TO 19 AND REQUIRED THE ANNUAL MEETING OF THE BOARD OF DIRECTORS TO TAKE PLACE WITHIN 90 DAYS BEFORE THE EXPIRATION OF THE FISCAL YEAR. DESCRIBE THE PROCESS USED BY MGMT AND/OR GOV BODY TO REVIEW 990 FORM 990, PART VI, QUESTION 11B MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING. DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFL OF INTER FORM 990, PART VI, QUESTION 12C KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, AND EMPLOYEE TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR INTERNAL AUDIT, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN PRODUCES AN ANNUAL SURVEY REQUIRING ALL BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM. OFFICES & POSIT. FOR WHICH PROCESS WAS USED, & YEAR PROCESS BEGUN FORM 990, PART VI, QUESTION 15A & 15B THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2019, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. AVAIL OF GOV DOCS, CONFLICT OF INTEREST, &FIN STMTS TO GEN PUBLIC FORM 990, PART VI, QUESTION 19 KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST. ADDITIONAL DETAIL ON GRANTS FORM 990, PART IX, LINE 1 For more than 35 years, Susan G. Komen has been working toward its vision of creating a world without breast cancer through its mission of ensuring all people get access to the care they need and investing in breakthrough research to better detect, prevent and treat breast cancers at every stage, and ultimately, to discover the cures. As a result of the economic and healthcare system impacts from the COVID-19 pandemic, in May 2020 Komen began a series of changes to strengthen its financial and operational position to continue to deliver on its vision and mission. Komen began a process to centralize all operations, consolidating its independent Affiliates into its headquarters organization, resulting in a single organization. This consolidation will enable Komen to leverage the combined expertise of its mission leaders to deliver a united mission program, utilizing technology as a key driver to connect to people who need to access care where they are and to help improve the patient experience; resulting in administrative and operational efficiencies. Komen implemented additional cost reduction measures including reducing headquarters staff by 24% in the first quarter and our Affiliates who will consolidate in FY21 experienced a 67% staff reduction. Our consolidated headcount is anticipated to be reduced by at least 33% less than prior fiscal year, pre-pandemic. In addition, salaries were reduced by 5% - 15% with higher level positions taking the larger percentage reductions. Komen also suspended its 403B match program for the remaining months in 2020. These changes will be reflected in the 990 filed for our FY21 Fiscal Year. Central to Komens vision is a steadfast commitment to investing in breakthrough research. In response to the COVID-19 pandemics impact on the health care system, including suspension of non-pandemic related medical research at most research universities across the country, Komen did not award new grants in FY2020. To be clear, our commitment to saving lives by investing in breakthrough research and meeting the most critical needs in communities is unchanged and unwavering. Despite the economic uncertainty and challenging fundraising environment, Komen maintained its commitment to all awarded projects. We currently have an incredible portfolio of nearly 200 research grants, about half which are focused on recurrence and metastasis. In fact, since 1982 our total investment in metastatic breast cancer research has reached more than $210 million, supporting over 500 research grants and 50 clinical trials almost 100 of these Komen-funded research projects are still active. In addition, 43 of our ongoing research projects involve clinical trials, speeding discovery to patient benefit. Another priority for our research is to better understand and develop solutions for the disparities in breast cancer outcomes, particular for people of color. In fact, 24 of our current research projects are focused on this, including $1 million in new grants we awarded this fiscal year. ADDITIONAL DETAIL ON EVENT PROD. EXPENSES INCLUDED ON OTHER EXPENSE FORM 990, PART IX, LINE 24 KOMEN PAYS 50% OF THE COST OF ALL T-SHIRTS FOR THE 111 SUSAN G. KOMEN RACE FOR THE CURE AND MORE THAN PINK WALK EVENTS CONDUCTED BY THE KOMEN AFFILIATES DURING THE FISCAL YEAR. RACE FOR THE CURE AND MORE THAN PINK WALK EVENTS CONDUCTED BY THE KOMEN AFFILIATES DURING THE FISCAL YEAR. OTHER CHANGES IN NET ASSETS OR FUND BALANCES FORM 990, PART XI, LINE 9 RESCINDED GRANTS $798,867 ------------ TOTAL $798,867 ============